$29.520
+0.009 (+0.03%)收盤時
COGT 資訊
COGT 事件
Cogent Biosciences' New Drug Application Accepted by FDA, Target Date June 29, 2027
Cogent Biosciences announced that the FDA has accepted its new drug application for bezuclastinib in patients with Advanced Systemic Mastocytosis and assigned a Prescription Drug User Fee Act target action date of June 29, 2027. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues.
H.C. Wainwright Gives Cogent Buy Rating
Cogent's Q2 results were broadly in line with expectations, with higher-than-expected operating expenses driving a lower FY26 EPS forecast, but $866M of cash provides runway into late 2028 while two possible upcoming bezuclastinib approvals and a potentially attractive M&A profile support a Buy rating, H.C. Wainwright tells investors in a research note.
Cogent Biosciences Submits NDA for Bezuclastinib
Cogent Biosciences announced it has submitted its new drug application, or NDA, to the FDA for bezuclastinib in Advanced Systemic Mastocytosis. The submission is based on clinical data from the APEX pivotal trial.
Cogent Biosciences Announces GIST Clinical Trial Data
Cogent Biosciences announced detailed clinical data from the primary analysis of the PEAK Phase 3 trial of bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal Tumors, GIST, who have received prior treatment with imatinib. The presentation titled Primary Results of the Phase 3 Peak Study of Bezuclastinib + Sunitinib vs Sunitinib Monotherapy in Advanced Gastrointestinal Stromal Tumors will be presented. Key highlights: Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months for bezuclastinib combination compared to sunitinib alone; Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations; Mean duration of treatment estimated at 21.4 months for patients receiving bezuclastinib combination; Bezuclastinib combination well tolerated with no unique risks observed with the combination when compared to the known safety profile of sunitinib; Priority Review granted following FDA acceptance of NDA for bezuclastinib combination in GIST patients who previously received imatinib; PDUFA date scheduled for November 30, 2026
Cogent Biosciences' NDA for Bezuclastinib Accepted by FDA for Priority Review
Cogent Biosciences announced that the FDA has accepted its new drug application, or NDA, for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors, or GIST, who have received prior treatment with imatinib. The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act target action date of November 30. In addition, the FDA communicated that at this time, there is no plan to hold an advisory committee, nor have they identified any potential review issues.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。